Following an investigational new drug application clearance from the FDA, a phase 1 trial plans to evaluate CD-001.

Generative AI can design never-before-seen proteins quickly and at scale, streamlining the drug design process like never ...

The Food and Drug Administration (FDA) has cleared an investigational new drug application for the novel treatment, APTN-101, ...

The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.

Scientists have discovered that a protein linked to prostate cancer is associated with more aggressive disease—it could be a ...

Developing advanced drug screening tools is crucial for the advancement of personalized medicine and the creation of more ...

Key Takeaways Arrowhead Pharmaceuticals reported a Phase-3 study of its medicine for a rare genetic disorder met all its ...

In the constantly evolving field of molecular biology, one of the most challenging tasks has been designing proteins that can ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...

The market for weight-loss treatments is expected to see 16 new drugs vying for a slice of the lucrative business currently dominated by Novo Nordisk and Eli Lilly, according to estimates from ...

Astrocytes in the brain exhibit significant regional diversity, but the mechanisms controlling their heterogeneity remain ...